Research and Development

The Challenge

The most pressing challenge in drug development today is the high rate of attrition. To meet this challenge, there has been a major shift towards automation and the development of personalized medicine. These two approaches promise to deliver better response rates, identify toxicity issues earlier and reduce time-to-market.

Imaging is vital in every area of biomedical research. Advances in technologies such as microscopy, image acquisition, biomarkers, and data management, have dramatically increased the number of digital images. In the majority of cases, however, state-of-the-art image analysis technology fails to automatically address the required segmentation tasks and consequently fails to provide sufficiently detailed quantification of image content. The task of image analysis usually falls to domain experts – it is a time-consuming process when performed manually, and the outcomes are typically subjective and qualitative rather than quantitative. This situation is causing a major bottleneck.

How Definiens Helps

Definiens’ technology provides unmatched versatility and power for 2D and 3D image analysis in all disease areas and at every stage – high-content screening, tissue analysis and in-vivo imaging. This supports translational research and the development of personalized medicine.

Definiens’ technology addresses even highly complex segmentation problems and can deal with all forms of variations: phenotypic, staining, illumination, and structural heterogeneity. As a result, you get consistent detection of all the relevant regions and structures of interest and superbly detailed quantification.

Discovery
Pre-clinical Safety
Clinical Trials
Diagnostic Development